The GIP receptor component is believed to enhance metabolic and weight-loss effects, whilst glucagon receptor activation is hypothesised to increase energy expenditure and promote hepatic fat breakdown (lipolysis)
According to the annual KFF Employer Health Benefits Survey, coverage for obesity medications among very large employers rose to 43% this year, up from 28% last year
Generic market entry On 21 March, Dr Reddys, Sun Pharma, Zydus Lifesciences, Glenmark, Alkem, and Natco launched generic semaglutide formulations
Kimberly Anne Gudzune of @HopkinsMedicine, recorded @SocietyGIM #SGIM23 in Denver, Colorado Show Segments Intro Barriers to treating medicine in primary care Patient counseling and obesity pathophysiology Motivational Interviewing Telemedicine for obesity Tools and tips for a weight loss program Medications for Obesity GLP1 agonist prescribing tips Outro Obesity Medicine Pearls Obesity is a chronic disease
Others use them for a defined period to reach a target weight, then transition off with close monitoring